Suppr超能文献

聚山梨酯与替代表面活性剂在酯酶存在下对界面张力保护和脂肪酸颗粒形成缓解作用的比较。

A comparison of Polysorbates and Alternative Surfactants for Interfacial Stress Protection and Mitigation of Fatty Acid Particle Formation in the Presence of an Esterase.

机构信息

Drug Product Development, BioTherapeutics Development and Supply, Janssen Research & Development, 200 Great Valley Parkway, Malvern, PA 19355, USA.

Analytical Development, BioTherapeutics Development and Supply, Janssen Research & Development, Hochstrasse 201, Schaffhausen 8200, Switzerland.

出版信息

J Pharm Sci. 2024 Sep;113(9):2688-2698. doi: 10.1016/j.xphs.2024.07.010. Epub 2024 Jul 14.

Abstract

The hydrolysis of polysorbate surfactants in large molecule drug product formulations caused by residual host cell proteins presents numerous stability concerns for pharmaceuticals. The fatty acids (FA) released by polysorbate hydrolysis can nucleate into particulates or challenge the conformational stability of the proteinaceous active pharmaceutical ingredient (API). The loss of intact polysorbate may also leave the Drug Product (DP) vulnerable to interfacial stresses. Polysorbate 20 and 80 are available in several different quality grades (Multi-compendial, Super Refined, Pure Lauric Acid (PLA)/Pure Oleic Acid (POA)). All variations of polysorbate as well as three alternative surfactants: Brij L23, Brij O20 and Poloxamer 188 were compared for their ability to protect against air-water interfacial stresses as well as their risk for developing particulates when in the presence of lipoprotein lipase (LPL) (Pseudomonas). Results show a meaningful difference in the timing and morphology of FA particle formation depending on the type of polysorbate used. All grades of polysorbate, while susceptible to hydrolysis, still offered sufficient protection to interfacial stresses, even when hydrolyzed to concentrations as low as 0.005 % (w/v). Alternative surfactants that lack an ester bond were resistant to lipase degradation and showed good protection against shaking stress.

摘要

大分子药物制剂中残留的宿主细胞蛋白会导致聚山梨酯表面活性剂发生水解,这给药物带来了诸多稳定性问题。聚山梨酯水解产生的脂肪酸(FA)会成核形成颗粒,或对蛋白质活性药物成分(API)的构象稳定性造成挑战。聚山梨酯的完整性丧失也可能使药物产品(DP)易受界面应力的影响。聚山梨酯 20 和 80 有多种不同的质量等级(多药典级、特级精制级、纯月桂酸(PLA)/纯油酸(POA)级)。比较了所有聚山梨酯变体以及三种替代表面活性剂:Brij L23、Brij O20 和泊洛沙姆 188,以评估它们在存在脂蛋白脂肪酶(LPL)(假单胞菌)时防止气-液界面应力以及形成颗粒的风险的能力。结果表明,根据所使用的聚山梨酯类型,FA 颗粒形成的时间和形态存在显著差异。尽管所有等级的聚山梨酯都容易发生水解,但即使水解至 0.005%(w/v)的低浓度,仍能对界面应力提供足够的保护。缺乏酯键的替代表面活性剂不易受到脂肪酶的降解,并且对振动应力有良好的保护作用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验